Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

Table 1 Patient characteristics

No.	Age	Gender	BSA (m²)	MSKCC risk	Metastatic sites	Prior therapy
1	70	Female	1.298	Intermediate	Lung, Lymph nodes	None
2	58	Female	1.446	Favorable	Abdominal wall, Lung, liver	None
3	56	Male	1.929	Intermediate	Lung	Interferon
4	79	Male	1.710	Favorable	Pancreas, Contralateral kidney	None
5	62	Male	1.893	Favorable	Pleura	None
6	64	Male	1.659	Intermediate	Lung	None

BSA, body surface area; MSKCC, Memorial Sloan-Kettering Cancer Center classification.

ISSN: 1756-0500